Rituximab Maintenance Treatment for a Maximum of 5 Years In Follicular Lymphoma: Safety Analysis of the Randomized Phase III Trial SAKK 35/03
Christian Taverna(Kantonsspital St. Gallen), Michele Ghielmini(Institute of Oncology Research), Mathew Simcock(Swiss Group For Clinical Cancer Research), Thomas Pabst(University Hospital of Bern), Walter Mingrone(Kantonsschule Olten), Auro del Giglio(Faculdade de Medicina do ABC), Simona Bassi(European Institute of Oncology), Felicitas Hitz(Kantonsspital St. Gallen), Lidija Čevreska(Kantonsspital St. Gallen), Daniel Vorobiof(The Medical Oncology Centre of Rosebank)
Cited by 24
Related Papers
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications
|Photodiagnosis and Photodynamic Therapy|2005|910
Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer
|Journal of Clinical Oncology|1999|639
The biology of cancer-related fatigue: a review of the literature
|Supportive Care in Cancer|2015|305